Pacific Biosciences of California announced Q2 2026 financial results with total revenue of $39.0 million and a GAAP net loss of $44.7 million, while providing full-year 2026 revenue guidance of $155 million to $165 million. The Board approved a restructuring plan targeting the elimination of approximately 8% of its workforce (40 employees) to reduce annualized operating expenses by $30 million to $40 million by end-2027, incurring estimated pre-tax charges of $2.0 million. Concurrently, Mark Van Oene succeeded Christian Henry as President and CEO effective August 5, 2026. Van Oene’s compensation includes a $743,000 base salary and equity grants valued at $2.25 million, while Henry will serve as Senior Business Advisor through December 31, 2026, with a separation payment of approximately $1.16 million upon transition completion. Pacific Biosciences operates in the life science technology industry, designing and manufacturing advanced genomic sequencing solutions.

Christopher M. Smith resigned from the Board of Directors of Pacific Biosciences of California, Inc., effective July 8, 2026. The company stated there were no disagreements regarding operations, policies, or practices related to his departure. Pacific Biosciences of California, Inc. is a biotechnology company that provides long-read sequencing solutions.